Protara Therapeutics, INC 8-K filings

Protara Therapeutics announced its second quarter 2026 financial results, highlighting progress in its clinical trials for TARA-002 and IV Choline Chloride, with a cash runway extending into 2028.

Protara Therapeutics, Inc. reported the resignation of its Chief Medical Officer, Leonardo Viana Nicacio, M.D., effective June 26, 2026, with his responsibilities to be absorbed by existing leadership.

Protara Therapeutics held its Annual Meeting on June 12, 2026, with stockholders approving key proposals including director elections, auditor ratification, and amendments to increase authorized shares and allow officer exculpation.

Protara Therapeutics announced Q1 2026 financial results, highlighting progress in TARA-002 development for lymphatic malformations and bladder cancer, with cash reserves projected into 2028.

Protara verified a 68.0% six‑month complete response in 25 BCG‑unresponsive NMIBC patients, triggering the exercise window for $5.25 warrants through June 29, 2026.

Protara Therapeutics announced positive interim Phase 2 data for TARA-002 in non-muscle invasive bladder cancer, demonstrating compelling response rates and a favorable safety profile.

Protara Therapeutics, Inc. announced the completion of its public offering, including the full exercise of the underwriters' option, raising approximately $86.3 million in gross proceeds.

Protara Therapeutics, Inc. successfully closed a public offering of 13,043,479 shares of common stock, raising approximately $75 million in gross proceeds to fund clinical development.

Protara Therapeutics announced positive interim Phase 2 data for TARA-002 in BCG-Nave NMIBC patients, demonstrating high complete response rates and a favorable safety profile, alongside key FDA alignment.

Protara Therapeutics announced positive interim results from its Phase 2 STARBORN-1 trial for TARA-002 in pediatric Lymphatic Malformations, demonstrating high clinical success rates and a favorable safety profile.

Protara Therapeutics announced its third quarter 2025 financial results, reporting an increased net loss and providing updates on its TARA-002 and IV Choline Chloride clinical programs.

Protara Therapeutics announced its second quarter 2025 financial results, reporting a net loss of $15.0 million and providing updates on its clinical pipeline, including TARA-002 and IV Choline Chloride.

Protara Therapeutics, Inc. announced that its stockholders approved all proposals at the Annual Meeting held on June 11, 2025, including the election of three Class II directors, ratification of Ernst and Young LLP as auditors, approval of executive compensation, and an amendment to the 2024 Equity Incentive Plan.

Protara Therapeutics reports positive interim results from its ADVANCED-2 trial of TARA-002 in NMIBC and provides a business update alongside its Q1 2025 financial results.

Protara Therapeutics reports promising interim data from its Phase 2 ADVANCED-2 trial, showcasing durable responses with TARA-002 in patients with Non-Muscle Invasive Bladder Cancer (NMIBC).

Protara Therapeutics reports positive six-month data from the ADVANCED-2 trial, anticipates key milestones in 2025, and boasts a strong cash position extending into 2027.

Protara Therapeutics highlights positive interim results from the ADVANCED-2 trial, completion of a $100 million public offering, and anticipated 2025 milestones across its NMIBC and rare disease programs.

Protara Therapeutics successfully closed a $100 million public offering to fund the clinical development of TARA-002 and other programs.

Protara Therapeutics reports promising interim results from its Phase 2 ADVANCED-2 trial of TARA-002, showing significant complete response rates in patients with non-muscle invasive bladder cancer.

Protara Therapeutics announced its third quarter 2024 financial results and provided a business update, highlighting progress in its clinical programs and upcoming data readouts.

Protara Therapeutics announced its second quarter 2024 financial results, highlighted by progress in its TARA-002 and IV Choline Chloride programs, and expects cash resources to fund operations into 2026.

Protara Therapeutics held its annual meeting on June 7, 2024, where stockholders elected three Class I directors, ratified the selection of Ernst and Young LLP as the independent auditor, and approved the compensation of named executive officers, the 2024 Equity Incentive Plan, and the 2024 Employee Stock Purchase Plan.

Protara Therapeutics announced positive clinical data for its TARA-002 program in bladder cancer, aligned with the FDA on a path for IV Choline Chloride, and secured $45 million in funding, extending its operational runway into 2026.

Protara Therapeutics has successfully raised $45 million through a private placement to fund its clinical programs and extend its cash runway into 2026.

Protara Therapeutics' Chief Medical Officer, Jathin Bandari, M.D., will resign effective April 11, 2024, and transition into a consulting role.

Protara Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting progress in its clinical programs and providing a business update.